Maxona Pharmaceuticals

Maxona Pharmaceuticals is a clinical-stage pharmaceutical company developing MAX-001, a proprietary optimized extended-release solid oral formulation of nefopam. Its initial focus is new therapies that treat acute and chronic pain without the side effects and addiction risks associated with NSAIDs and opioids; MAX-001 is designed to deliver both a rapid onset and extended duration of analgesia.

Maxona Pharmaceuticals targets patients in the United States with acute and chronic pain. The active molecule in MAX-001 has been used outside the United States for decades to treat moderate to severe pain. If authorized for use in the United States, MAX-001 would be the only triple monoamine re-uptake inhibitor indicated for acute pain.